Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AD 32; N-Trifluoroacetyladriamycin-14-valerate; NSC 246131; Valstar; Valtaxin

Latest Information Update: 24 Jul 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anthra Pharmaceuticals
  • Developer Endo Pharmaceuticals Solutions
  • Class Anthracyclines; Antineoplastics; Cytostatics; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Bladder cancer
  • Discontinued Endometrial cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jul 2012 CTP alert for NCT01606345 - Endo Pharma is only the collaborator - not added
  • 14 Feb 2012 Endo Pharmaceuticals terminates a phase III trial in Bladder cancer in USA (NCT01310803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top